Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2023-179981

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Association of Patient Characteristics and Insurance Type with Multiple Myeloma Care Patterns

Hamlet Gasoyan, Faiz Anwer, Nicholas J Casacchia, Jeff Kovach, Jason Valent, Michael B. Rothberg

Blood (2023) 142 (Supplement 1): 7388.

https://doi.org/10.1182/blood-2023-182003

Published: 2023

Journal Articles

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Louis S. Williams, Bardia Khosravi, Marko Velimirovic, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Hussein Awada, Danai Dima, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2023-188762

Published: 2023

Journal Articles

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Danai Dima, Aishwarya Sannareddy, Nausheen Ahmed, James A Davis, Hira Shaikh, Zahra Mahmoudjafari, Marissa Duco, Jack Khouri, Gurbakhash Kaur, Jonathan Lochner, Faiz Anwer, Aimaz Afrough, Jason Valent, Hamza Hashmi, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2023-180458

Published: 2023

Journal Articles

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Hussein Awada, Ali Hajj Ali, Danai Dima, Craig S Sauter, Louis Williams, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Faiz Anwer

Blood (2023) 142 (Supplement 1): 7069.

https://doi.org/10.1182/blood-2023-189995

Published: 2023

Journal Articles

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Jr., Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 91.

https://doi.org/10.1182/blood-2023-180421

Published: 2023

Journal Articles

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Richa Manwani, Chandrasekhar Udata, Juliana Ianus, John Tripptree, Julia Catini, Candida Cristina Quarta

Blood (2023) 142 (Supplement 1): 540.

https://doi.org/10.1182/blood-2023-186515

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rajshekhar Chakraborty, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, Alok A. Khorana

Blood (2022) 140 (23): 2443–2450.

https://doi.org/10.1182/blood.2022015727

Published: 2022

Includes: Supplemental data

Journal Articles

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima, Ang Li, Lauren M. Granat, Puneet Dhillon, Carmelo Gurnari, Anirudh Yalamanchali, Saeid Mirzai, Wei Wei, Beth M. Faiman, Louis S. Williams, Sandra Mazzoni, Christy J. Samaras, Faiz Anwer, Jason Valent, Jack Khouri

Blood (2022) 140 (Supplement 1): 11299–11300.

https://doi.org/10.1182/blood-2022-165722

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Jack Khouri, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma

Chakra P Chaulagain, Maroun Bou Zerdan, Jack Khouri, Beth M. Faiman, Faiz Anwer, Chieh-Lin Fu, Jason Valent

Blood (2022) 140 (Supplement 1): 12530–12531.

https://doi.org/10.1182/blood-2022-157865

Published: 2022

Journal Articles

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Lauren M Granat, Hong Li, Faiz Anwer, Michael Sheu, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Rajshekar Chakraborty, Chakra P Chaulagain, Willem J. van Heeckeren, Louis S. Williams

Blood (2022) 140 (Supplement 1): 4290–4291.

https://doi.org/10.1182/blood-2022-168040

Published: 2022

NARROW

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Association of Patient Characteristics and Insurance Type with Multiple Myeloma Care Patterns

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only